Abstract: Arylsulphonamide derivatives of formula (I) and pharmaceutically acceptable salts thereof. The compounds may be useful for the treatment and/or prevention of disorders of the central nervous system.

Abstract: Arylsulphonamide derivatives of formula (I) and pharmaceutically acceptable salts thereof. The compounds may be useful for the treatment and/or prevention of disorders of the central nervous system.

Abstract: The invention relates to new compounds, 3-phenylpropionic acid derivatives of formula (I) wherein W represents COOH group or its bioisosters, or —COO—C1–C4-alkyl group; Y represents NH, N—C1–C10-alkyl, O, or S; X represents O, S, NH, N—C1–C10-alkyl, N-aryl, NSO2—C1–C10-alkyl, N—SO2-aryl, or N—SO2-heteroaryl; R1 to R8 each independently represents hydrogen atom or a substituent defined in the description; A is as defined in the description; n represents an integer from 0 to 4, inclusive; and pharmaceutically acceptable salts thereof.

Abstract: The invention relates to new compounds, being 3-phenylpropionic acid derivatives of formula I wherein W represents COOH group or its bioisosters, or —COO—C1-C4-alkyl group; Y represents NH, N—C1-C10-alkyl, O, or S; Z represents NH, N—C1-C10-alkyl, N-aryl, N-heteroaryl, S, or O; X represents O, S, NH, N—C1-C10-alkyl, N-aryl, NSO2—C1-C10-alkyl, N—SO2-aryl, or N—SO2-heteroaryl; R1 to R8 each independently represent hydrogen atom or a substituent defined in the description; A is as defined in the description; n represents an integer from 0 to 4, inclusive; and pharmaceutically acceptable salts thereof. The compounds are the ligands of PPAR-gamma receptor and are useful as medicaments.

Abstract: The invention relates to new compounds, being 3-phenylpropionic acid derivatives of formula I wherein W represents COOH group or its bioisosters, or —COO—C1-C4-alkyl group; Y represents NH, N—C1-C10-alkyl, O, or S; Z represents NH, N—C1-C10-alkyl, N-aryl, N-heteroaryl, S, or O; X represents O, S, NH, N—C1-C10-alkyl, N-aryl, NSO2—C1-C10-alkyl, N—SO2-aryl, or N—SO2-heteroaryl; R1, to R6 each independently represent hydrogen atom or a substituent defined in the description; A is as defined in the description; n represents an integer from 0 to 4, inclusive; and pharmaceutically acceptable salts thereof. The compounds are the ligands of PPAR-gamma receptor and are useful as medicaments.

Abstract: The invention relates to new compounds, 3-phenylpropionic acid derivatives of formula (I) wherein W represents COOH group or its bioisosters, or —COO—C1-C4-alkyl group; Y represents NH, N—C1-C10-alkyl, O, or S; X represents O, S, NH, N—C1-C10-alkyl, N-aryl, NSO2—C1-C10-alkyl, N—SO2-aryl, or N—SO2-heteroaryl; R1 to R8 each independently represent hydrogen atom or a substituent defined in the description; A is as defined in the description; n represents an integer from 0 to 4, inclusive; and pharmaceutically acceptable salts thereof. The compounds are the ligands of PPAR-gamma receptor and are useful as medicaments.

Abstract: A method of treating overactive bladder in women involves inserting an intravaginal device of substantially spherical shape and a diameter that fits the width of the vagina into the vagina above the levator ani muscle, and maintaining said device in the appropriate location inside the vagina for an extended period of time to exert its therapeutic effect. The method may further comprise performing pelvic floor exercises, preferably exercises consisting of contracting the levator ani muscle and squeezing soft objects between the knees while in a prone position, preferably twice a day, with said device left inside the vagina.

Abstract: The invention provides a novel association of polyvinylpyrrolidone with chlorin p6 and/or its salt with a pharmaceutically acceptable counter-ion and a method of preparation thereof. Preferably, the weight ratio of chlorin p6 and/or its salt with a pharmaceutically acceptable counter-ion to polyvinylpyrrolidone is contained within the range from about 1:1 to about 1:200. The association can be used as a photosensitizer in photodynamic therapy and/or diagnostics or for photochemical internalization of molecules as well as a photosensitizer in cosmetology. The invention provides also a pharmaceutical composition containing the novel association, a method of treating and diagnosing diseases by a dynamic phototherapy and a method of performing cosmetic procedures with the use of the novel association as a photosensitizer.

Abstract: A method of treating overactive bladder in women involves inserting an intravaginal device of substantially spherical shape and a diameter that fits the width of the vagina into the vagina above the levator ani muscle, and maintaining said device in the appropriate location inside the vagina for an extended period of time to exert its therapeutic effect. The method may further comprise performing pelvic floor exercises, preferably exercises consisting of contracting the levator ani muscle and squeezing soft objects between the knees while in a prone position, preferably twice a day, with said device left inside the vagina.